Immunetics Receives $500,000 from Massachusetts Life Sciences Center to Commercialize BacTx® Test for Bacterial Contamination in Platelet TransfusionsBusiness Matching Grant (SBMG) to commercialize its BacTx® rapid test for detecting bacterial contamination in platelets.
Platelets are a vital blood product enabling clotting, and patients suffering from trauma, surgical procedures, cancer, or chemotherapy must receive platelet transfusions to survive. Bacterial contamination of platelets is the leading cause of infection during transfusion, with patients facing the risk of severe or fatal transfusion-associated sepsis from the roughly 1 in 2,000 platelet units that are contaminated.
"Rapidly detecting bacteria in platelet units presents a major challenge. Some current testing methods are ineffective because of low sensitivity. Others are overly difficult or time-consuming to perform close to transfusion," said Dr. Andrew Levin, president and scientific director, Immunetics.
"According to the American Association of Blood Banks (AABB), a rapid test with high sensitivity performed close to the time of transfusion would represent a breakthrough in transfusion safety. The Massachusetts Life Sciences Center grant will help us transition the critical juncture from R&D to manufacturing scale-up and regulatory approval — and commercially launch BacTx," Levin said.
Immunetics has concluded clinical trials for BacTx® and plans to submit an application for approval to the U.S. Food and Drug Administration (FDA) this summer. With FDA approval, BacTx® could be launched as early as this year.
Immunetics was one of four life sciences firms named by the Massachusetts Life Sciences Center’s Board of Directors ("the Center") to share in $2 million in new SBMGs. The four recipients were chosen through a competitive process after extensive review by the Center’s peer review panel, Scientific Advisory Board, and Board of Directors. The grants foster job growth and technology commercialization in the Massachusetts Life Sciences Supercluster.
"Helping our life sciences companies grow is all about creating jobs," said Governor Deval Patrick. "As we continue to strengthen our global leadership in the life sciences, the Center’s Small Business Matching Grant Program is meeting an important need and making Massachusetts an even more attractive place for life sciences companies to locate and grow."
"The SBMG program is another example of the Center’s leveraging strategy," said Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center. "Federal SBIR/STTR grants provide Massachusetts companies with funds for their research and development; our SBMG program then provides the funds that companies need to bridge to commercialization. These four promising companies will bring cost-effective new treatments to the market and expand employment opportunities in Massachusetts. We are especially pleased that some of our grantees will contribute directly to the creation of biomanufacturing jobs in the Commonwealth."
"As an author of the legislation creating the Life Sciences Center several years ago, I am excited about the wonderful opportunity to grow the Life Sciences industry on the South Boston Waterfront," said State Senator Jack Hart (D-South Boston).
"Immunetics is doing important work to prevent infectious disease and improve public health in our state and around the world," said State Representative Nick Collins (D-South Boston), a member of the Joint Committee on Economic Development and Emerging Technologies. "This award by the Massachusetts Life Sciences Center is an example of the Commonwealth’s commitment to investing in our state’s economic future. It is also another sign of the continued emergence of the South Boston Waterfront as a center for innovation and job creation in the life sciences industry."
"I am extremely grateful for the continuing support by the Commonwealth and the Massachusetts Life Sciences Center of our mission to introduce innovations in the diagnosis of infectious diseases, as we grow our company in South Boston and become a stronger part of — and employer in — the very exciting Massachusetts Life Sciences community," Levin said.
Immunetics received two SBIR Phase II grants totaling approximately $4 million from the National Heart, Lung, and Blood Institute (NHLBI), an agency of the National Institutes of Health (NIH), which supported the research and development of the test. The technology underlying the test is protected by a recently issued U.S. patent, and foreign patents with approved claims are in process of issue.
With FDA approval, the BacTx® test will be marketed to blood centers and hospitals throughout the U.S. and around the world. In total, about 5 million platelet units are collected annually in the U.S. and an equal number outside the U.S.
About Immunetics, Inc.
Immunetics Inc. (http://www.immunetics.com), offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection, and for over 10 years has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is to deliver better, cost-efficient care through more accurate diagnosis. Immunetics is headquartered in Boston, Mass. Follow Immunetics on Twitter at http://twitter.com/immunetics.
27 Drydock Ave
Boston, MA 02210 USA
Press Contact: Don Goncalves, Tiziani Whitmyre, 781-793-9380, email@example.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immunetics Receives $500,000 from Massachusetts Life Sciences Center to Commercialize BacTx® Test for Bacterial Contamination in Platelet Transfusions here
News-ID: 177400 • Views: 1133
More Releases from Immunetics
Immunetics Awarded $2.4 Million NIH Grant for Clinical Trials of New Blood Test …
Immunetics, Inc. today announced it has been awarded a $2.4 million, 3-year Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (NIH), to support clinical trials of the company's new confirmatory test for Chagas’ disease, a serious and potentially fatal parasitic infection. Chagas' disease is endemic in large parts of Latin America, where it affects up to 11
More Releases for Mass
Can Manufacturers Keep up with Mass Customization?
We take a look at how leading-edge manufacturing companies are profiting from increased sales and customer loyalty thanks to sophisticated order management systems, responsive supply chains, and flexible production techniques that allow their consumers to order highly customized products direct from the factory. THE RISE OF MASS CUSTOMIZATION COMPANIES: BECAUSE EVERYONE WANTS TO BE UNIQUE In today's world of wide-ranging consumer choice, it's hard to wrap your head around the fact that
Clinical Mass Spectrometry Market Report 2018: Segmentation by Product (GAS Chro …
Global Clinical Mass Spectrometry market research report provides company profile for Agilent Technologies , Waters, Shimadzu Corporation, Danaher, PerkinElmer Inc., Thermo Fisher Scientific Inc., Bruker, Mass Spectrometry Instruments (MSI), Kore technology and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for
Global Liquid Chromatography-Mass Spectroscopy Market | MarketResearchReports.bi …
Latest industry research report on: Global Liquid Chromatography-Mass Spectroscopy Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The use of liquid chromatography along with high-resolution mass spectroscopy has advanced spectacularly over the last two decades in identifying unknown contaminants. Development of new instrumentation is the key reason of this tremendous development in the global liquid chromatography-mass spectroscopy market. Due to advantages such as sample pre-treatment
Mass Communication Global Market Briefing
Report Hive Market Research Released a New Research Report of 32 pages on Title "Mass Communication Global Market Briefing" with detailed Analysis, Forecast and Strategies. Mass correspondence is the investigation of how individuals trade data through broad communications to vast fragments of the populace in the meantime. At the end of the day, mass correspondence alludes to the bestowing and trading of data on an extensive scale to an extensive
Mass Spectrometry Technologies Market Analysis
Mass Spectrometry has been applied in life science research for over 40 years. Over these years several technological advancements have evolved to cater specific requirements in various life science areas. The mass spectrometry market had observed an all-time low between 2008 and 2010, largely due to economic crisis that took place globally. This has changed as MS has observed a progressive growth due to increasing demand from research facilities, increased
Targeting UK Mass Affluents With Insurance
Summary The mass affluent population in the UK is growing, meaning the demographic is an opportunity for providers selling personal insurance. Mass affluents are more likely to be male, have higher household incomes, and be married compared to retail customers. The assets of mass affluents are higher value, making their insurance needs more complex. They have different lifestyles compared to retail customers, meaning they also have different insurance needs. They travel